aripiprazole has been researched along with escitalopram in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 12 (85.71) | 2.80 |
| Authors | Studies |
|---|---|
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bucki, A; Głuch-Lutwin, M; Jakubczyk, M; Jamrozik, M; Jastrzębska-Więsek, M; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Pytka, K; Siwek, A; Śniecikowska, J; Wesołowska, A; Zagórska, A | 1 |
| Alciati, A; Caldirola, D; Cuniberti, F; Daccò, S; De Berardis, D; Perna, G | 1 |
| Chakrabarty, T; Frey, BN; Kennedy, SH; Lam, RW; McInerney, SJ; Milev, RV; Müller, DJ; Rotzinger, S; Torres, IJ | 1 |
| Bhat, V; Chakrabarty, T; Frey, BN; Giacobbe, P; Kennedy, SH; Lam, RW; Lou, W; McInerney, S; Michalak, EE; Milev, RV; Morton, E; Müller, DJ; Parikh, SV; Rotzinger, S | 1 |
| Allen, TA; Frey, BN; Harkness, KL; Kennedy, SH; Lam, RW; Milev, R; Mueller, DJ; Quilty, LC; Uher, R | 1 |
| Kamińska, K; Lech, MA; Leśkiewicz, M; Lorenc-Koci, E; Rogóż, Z | 1 |
| Bhat, V; Demchenko, I; Espinola, CW; Frey, BN; Ho, K; Kennedy, SH; Khoo, Y; Lam, RW; Lou, W; Milev, RV; Parikh, SV; Parmar, R; Ravindran, AV; Rotzinger, S | 1 |
| Bhat, V; Diep, C; Frey, BN; Gandhi, W; Kennedy, SH; Khoo, Y; Ladha, KS; Lam, RW; Lou, W; Milev, RV; Ravindran, AV; Rosenek, N; Rotzinger, S; Salomons, T; van Reekum, CM | 1 |
| Farzan, F; Foster, JA; Frey, BN; Husain, MI; Kennedy, SH; Kim, HK; Kloiber, S; Lam, RW; Milev, R; Müller, DJ; Mulsant, BH; Parikh, SV; Soares, CN; Tripathy, SJ; Turecki, G; Zai, G | 1 |
| Blier, P; Farzan, F; Foster, JA; Frey, BN; Hassel, S; Islam, F; Kennedy, SH; Lam, RW; Leri, F; Magarbeh, L; Marshe, VS; Milev, RV; Müller, DJ; Parikh, SV; Placenza, F; Rotzinger, S; Soares, CN; Strother, SC; Taylor, VH; Turecki, G; Uher, R | 1 |
| Burns, L; Cogan, ES; Fowler, A; Gardiner, A; Ghosh, P; Hain, D; Johnson, H; Kenan, W; Lewis, D; Liebelt, E; Limdi, N; Martinez, J; Shah, N; Shelton, R | 1 |
| Lu, Z; Wang, Y; Xun, G | 1 |
2 review(s) available for aripiprazole and escitalopram
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review.
Topics: Adult; Antidepressive Agents; Aripiprazole; Child; Child Abuse; Clinical Decision-Making; Clinical Trials as Topic; Depressive Disorder, Major; Escitalopram; Humans; Observational Studies as Topic; Precision Medicine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 2021 |
3 trial(s) available for aripiprazole and escitalopram
| Article | Year |
|---|---|
Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Topics: Adolescent; Adult; Antidepressive Agents; Aripiprazole; Biomarkers; Canada; Cognition; Cognitive Dysfunction; Depressive Disorder, Major; Drug Therapy, Combination; Escitalopram; Female; Humans; Male; Middle Aged; Young Adult | 2021 |
Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.
Topics: Antidepressive Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Escitalopram; Humans; Pain; Pain Measurement; Treatment Outcome | 2022 |
Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial.
Topics: Antidepressive Agents; Aripiprazole; Citalopram; Cognition; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2024 |
9 other study(ies) available for aripiprazole and escitalopram
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD).
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzoxazoles; Dementia; Dizocilpine Maleate; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Humans; Male; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2020 |
Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.
Topics: Activities of Daily Living; Adult; Antidepressive Agents; Aripiprazole; Canada; Depressive Disorder, Major; Drug Monitoring; Drug Therapy, Combination; Escitalopram; Female; Humans; Male; Physical Functional Performance; Psychiatric Status Rating Scales; Quality of Life; Social Interaction; Treatment Outcome | 2021 |
Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CAN-BIND 1 report.
Topics: Aripiprazole; Depression; Depressive Disorder, Major; Escitalopram; Humans; Neuroticism | 2021 |
Impact of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behaviors and BDNF mRNA expression in the adult Sprague-Dawley rats exposed to glutathione deficit during early postnatal development of the brain.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Escitalopram; Glutathione; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2021 |
Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.
Topics: Aripiprazole; Depression; Depressive Disorder, Major; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Escitalopram; Humans; Treatment Outcome | 2022 |
Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study.
Topics: Aripiprazole; Biomarkers; Canada; Depressive Disorder, Major; Double-Blind Method; Endocannabinoids; Escitalopram; Genome-Wide Association Study; Humans; RNA, Messenger; Treatment Outcome | 2022 |
Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study.
Topics: Aripiprazole; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Escitalopram; Genotype; Humans; Treatment Outcome | 2022 |
Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department.
Topics: Adolescent; Aripiprazole; Child; Child, Preschool; Emergency Service, Hospital; Escitalopram; Humans; Pharmacogenetics; Psychotropic Drugs | 2023 |